MedTrace Logo

Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients

NCT00358488 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2016-10-28

No results posted yet for this study

Summary

This study is designed to determine the efficacy and safety of a new long-acting beta-agonist for asthma patients (GSK159797) following dosing for 14 days.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK159797 (10, 15, and 20mcg)

GSK159797 (10, 15, and 20mcg)

DRUG

salbutamol

salbutamol

DRUG

salmeterol 50mcg

salmeterol 50mcg

DRUG

placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • Germany
  • Netherlands
  • Russia
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00358488 on ClinicalTrials.gov